Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

As of April 30, 2025, there are 82 publicly listed companies in China engaged in the in vitro diagnostics (IVD) industry. Among them, 61 companies focus primarily on IVD, while 21 have IVD as part of their broader business portfolios.

According to Radio Television Hong Kong and Sing Tao Daily reports on February 20, a study found that the new coronavirus may cause hypogonadism and decreased fertility in male patients, and patients will still be affected after recovery.

Cytiva cooperates with General Biology (Anhui) Co., Ltd. to build the world's first oligo FlexFactory. The investment scale of the production base reaches hundreds of millions of CNY.

Chinese diagnostic firm Amoy Diagnostics announced on Wednesday that it has entered into a collaboration agreement with French pharmaceutical firm Pierre Fabre to develop companion diagnostic kits in China.

Roche announced on Wednesday that it received CE marking for two of its SARS-CoV-2 tests to run on the firm's new Cobas 5800 system.

On February 21, the Notification on Regulating the Adjustment of Some Medical Service Prices, which included 16 assisted reproductive technologies such as artificial insemination and embryo transfer into Beijing medical insurance, was issued.

Traces of the SARS-CoV-2 coronavirus that causes COVID-19 can be detected in microscopically small fluid droplets exhaled during a very short time span. This is the finding of a new study from the University of Gothenburg.

OraSure Technologies reported after the close of the market Wednesday that its fourth quarter 2021 revenues increased 1 percent year over year.

Agilent Technologies reported after the close of the market on Tuesday that its fiscal first quarter revenues rose 8 percent year over year.

Bio-Techne said on Tuesday that it has inked a development and license agreement with Thermo Fisher Scientific to complete development of and commercialize Bio-Techne's ExoTru kidney transplant rejection test, a multigene urine-based assay.

On February 23, Lepu Biopharma Co., Ltd. was listed on Hong Kong Exchanges and Clearing Limited (HKEX), stock code: 2157.HK. The issue price is HKD 7.13 per share, and public offering raised about HKD 900 million.